Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

被引：0
|
作者：
Cartron, Gillaume [1 ]
Garcia-Sancho, Alejandro Martin [2 ]
Reguera, Juan Luis [3 ]
Dahiya, Saurabh [4 ]
Guo, Shien [5 ]
Shi, Ling [5 ]
Eliason, Laurie [6 ]
Kumar, Jinender [6 ]
Farazi, Thalia [7 ]
Fasan, Omotayo [6 ]
Izutsu, Koji [8 ]
机构：
[1] Montpellier Univ Hosp Ctr, Clin Hematol Dept, Montpellier, France
[2] Univ Salamanca, Hosp Univ Salamanca, IBSAL, CIBERONC, Salamanca, Spain
[3] Univ Seville, Dept Hematol, Univ Hosp Virgen Rocio IBIS, Seville, Spain
[4] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Palo Alto, CA USA
[5] Evidera, Bethesda, MD USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] Bristol Myers Squibb, San Francisco, CA USA
[8] Natl Canc Ctr, Tokyo, Japan
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180175
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
    Abramson, Jeremy S.
    Palomba, Maria Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael L.
    Arnason, Jon E.
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison R.
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina
    Garcia, Jacob
    Kostic, Ana
    Li, Daniel
    Kim, Yeonhee
    Siddiqi, Tanya
    BLOOD, 2019, 134
  • [22] EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)
    Balasubramanian, N.
    Cummings, J.
    Lin, H.
    Raviele, A.
    Peng, L.
    Omidpanah, A.
    Espinola, R.
    Kostic, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S54 - S54
  • [23] CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
    Nishii, R.
    Lin, H.
    Chen, W.
    Balasubramanian, N.
    Cummings, J.
    Farazi, T.
    Fasan, O.
    Vedal, M.
    Lymp, J.
    Ogasawara, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S52 - S52
  • [24] Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
    Abramson, Jeremy S.
    Siddiqi, Tanya
    Gordon, Leo, I
    Lunning, Matthew Alexander
    Wang, Michael
    Arnason, Jon E.
    Mehta, Amitkumar N.
    Purev, Enkhee
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison R.
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina M.
    Garcia, Jacob
    Kostic, Ana
    Li, Daniel
    Kim, Yeonhee
    Palomba, Maria Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study
    Wierda, William G.
    Maloney, David G.
    Kenderian, Saad S.
    Brander, Danielle M.
    Papp, Eniko
    Ray, Pradipta
    Okal, Abood
    Perna, Serena K.
    Tuazon, Sherilyn A.
    Ou, San-San
    Ansari, Sahar
    Rane, Neha
    Shamsuzzaman, Md
    Ananthakrishnan, Revathi
    Jaskiewicz, Adam
    Peiser, Leanne
    Siddiqi, Tanya
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S346 - S346
  • [27] Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001
    Palomba, Maria Lia
    Siddiqi, Tanya
    Gordon, Leo I.
    Kamdar, Manali
    Lunning, Matthew A.
    Hirayama, Alexandre V.
    Abramson, Jeremy S.
    Arnason, Jon E.
    Ghosh, Nilanjan
    Mehta, Amitkumar
    Andreadis, Charalambos
    Solomon, Scott R.
    Kostic, Ana
    Singh, Ashvin
    Espinola, Ricardo
    Peng, Lily
    Ogasawara, Ken
    Chattin, Amy
    Wang, Michael L.
    BLOOD, 2023, 142
  • [28] Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001.
    Abramson, Jeremy S.
    Siddiqi, Tanya
    Garcia, Jacob
    Dehner, Christine
    Nguyen, Andy
    Snyder, Sophie
    Gitlin, Matthew
    Chung, Karen C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Braverman, Julia
    Liu, Fei Fei
    Lanar, Sally
    Miera, Matthew
    Shah, Selam
    Devlen, Jennifer
    Salles, Gilles
    BLOOD, 2021, 138
  • [30] Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Linhares, Yuliya
    Freytes, Cesar
    Cherry, Mohamad
    Bachier, Carlos
    Maris, Michael
    Hoda, Daanish
    Varela, Juan Carlos
    Bellomo, Courtney
    Cross, Scott
    Essell, James
    Fanning, Suzanne
    Terebelo, Howard
    Yimer, Habte
    Courtright, Jay
    Sharman, Jeff P.
    Vedal, Min
    Mailley, Connor
    Espinola, Ricardo
    Mattar, Bassam
    BLOOD, 2022, 140 : 10416 - 10418
12345